Skip to main content
ABVX
NASDAQ Life Sciences

Sofinnova Converts Royalties to Equity, Director Resigns from Abivax Board

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
7
Price
$119.86
Mkt Cap
$9.908B
52W Low
$5.59
52W High
$148.83
Market data snapshot near publication time

summarizeSummary

Sofinnova Crossover I SLP exchanged royalty certificates for $4.77 million in Abivax ADSs, increasing its voting stake to 6.7%, while its representative Kinam Hong resigned from the board.


check_boxKey Events

  • Sofinnova's Equity Conversion

    Sofinnova Crossover I SLP received 42,755 ADSs, valued at approximately $4.77 million, as part of Abivax's $90 million royalty certificate repurchase.

  • Increased Voting Stake

    Following the transaction, Sofinnova's voting rights in Abivax increased to 6.7% of the outstanding shares.

  • Director Resignation

    Kinam Hong, a member of Sofinnova's investment committee, resigned from Abivax's Board of Directors.


auto_awesomeAnalysis

This filing provides specific details on a significant capital event for Abivax, where it repurchased $90 million in royalty certificates, partly through issuing new shares. Sofinnova's participation in this transaction, converting its royalty interest into equity, updates its ownership structure and increases its voting stake to 6.7%. The simultaneous resignation of Kinam Hong, a representative of this major institutional investor, from the board is a notable governance change.

At the time of this filing, ABVX was trading at $119.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9B. The 52-week trading range was $5.59 to $148.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ABVX - Latest Insights

ABVX
May 11, 2026, 12:50 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
ABVX
May 07, 2026, 4:03 PM EDT
Filing Type: 6-K
Importance Score:
8
ABVX
Mar 23, 2026, 4:54 PM EDT
Filing Type: 20-F
Importance Score:
9
ABVX
Mar 23, 2026, 4:49 PM EDT
Filing Type: 6-K
Importance Score:
9
ABVX
Feb 23, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
8
ABVX
Jan 14, 2026, 4:13 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
ABVX
Jan 08, 2026, 9:21 AM EST
Filing Type: 144
Importance Score:
8